NxStage Medical (NXTM) Stock Price, News & Analysis

Company Overview

NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Key Stats

• Today's Range: $29.98 to $30.00
• 50-Day Range: $30.00 to $30.00
• 52-Week Range: $23.17 to $30.00
• Volume: 2.61 million shs
• Average Volume: 1.51 million shs
• Market Capitalization: $2.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NXTM Stock Analysis - Frequently Asked Questions

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) issued its earnings results on Monday, August, 7th. The medical device company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.00. The business's revenue was up .0% compared to the same quarter last year.

What other stocks do shareholders of NxStage Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NxStage Medical investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

Company Calendar

• Last Earnings: 8/07/2017
• Today: 3/14/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical Equipment
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:NXTM
• CIK: 1333170
• Web: www.nxstage.com
• Phone: 978-687-4700
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,470,000.00
• Net Margins: -1.29%
• Pretax Margin: N/A
• Return on Equity: -2.50%
• Return on Assets: -1.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.60
• Quick Ratio: 2.69

Sales & Book Value

• Annual Sales: $393.94 million
• Price / Sales: 5.08
• Cash Flow: $0.29 per share
• Price / Cash Flow: 103.07
• Book Value: $3.22 per share
• Price / Book: 9.32

Miscellaneous

• Outstanding Shares: 66,680,000
• Free Float: N/A
• Market Cap: $2.00 billion
• Optionable: Optionable
• Beta: 0.25